Report Detail

Pharma & Healthcare Global PPARα Agonist Market Growth 2022-2028

  • RnM4495403
  • |
  • 21 November, 2022
  • |
  • Global
  • |
  • 127 Pages
  • |
  • LPI(LP Information)
  • |
  • Pharma & Healthcare

Activation of PPAR-α reduces triglyceride levels and is involved in the regulation of energy homeostasis.

The global market for PPARα Agonist is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC PPARα Agonist market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States PPARα Agonist market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe PPARα Agonist market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China PPARα Agonist market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key PPARα Agonist players cover Ross Organic, BASF, Abmole, DXTPHARM and Ruiweier, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage
This latest report provides a deep insight into the global PPARα Agonist market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global PPARα Agonist market, with both quantitative and qualitative data, to help readers understand how the PPARα Agonist market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

Market Segmentation:
The study segments the PPARα Agonist market and forecasts the market size by Type (Phytol, Saroglitazar and Fenofibrate), by Application (Cirrhosis, Nonalcoholic Steatohepatitis, Regulate Blood Lipid and Others), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type
Phytol
Saroglitazar
Fenofibrate
CDDO-Im
Palmitoylethanolamide
Bavachinin
Clofibric Acid

Segmentation by application
Cirrhosis
Nonalcoholic Steatohepatitis
Regulate Blood Lipid
Others

Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Major companies covered
Ross Organic
BASF
Abmole
DXTPHARM
Ruiweier
BACHEM
Zydus Cadila
InvivoChem
APEXBIO
Abcam
Weikeqi-biotech
Solarbio
Nznutritionals
WEL-BLOOM Bio-Tech Corporation
Young Nutraceuticals
Biorbyt
BIOSYNTH
TargetMol
Bjbalb
Amgicam
Lupin

Chapter Introduction
Chapter 1: Scope of PPARα Agonist, Research Methodology, etc.
Chapter 2: Executive Summary, global PPARα Agonist market size (sales and revenue) and CAGR, PPARα Agonist market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: PPARα Agonist sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global PPARα Agonist sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global PPARα Agonist market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Ross Organic, BASF, Abmole, DXTPHARM, Ruiweier, BACHEM, Zydus Cadila, InvivoChem and APEXBIO, etc.
Chapter 14: Research Findings and Conclusion


1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global PPARα Agonist Annual Sales 2017-2028
    • 2.1.2 World Current & Future Analysis for PPARα Agonist by Geographic Region, 2017, 2022 & 2028
    • 2.1.3 World Current & Future Analysis for PPARα Agonist by Country/Region, 2017, 2022 & 2028
  • 2.2 PPARα Agonist Segment by Type
    • 2.2.1 Phytol
    • 2.2.2 Saroglitazar
    • 2.2.3 Fenofibrate
    • 2.2.4 CDDO-Im
    • 2.2.5 Palmitoylethanolamide
    • 2.2.6 Bavachinin
    • 2.2.7 Clofibric Acid
  • 2.3 PPARα Agonist Sales by Type
    • 2.3.1 Global PPARα Agonist Sales Market Share by Type (2017-2022)
    • 2.3.2 Global PPARα Agonist Revenue and Market Share by Type (2017-2022)
    • 2.3.3 Global PPARα Agonist Sale Price by Type (2017-2022)
  • 2.4 PPARα Agonist Segment by Application
    • 2.4.1 Cirrhosis
    • 2.4.2 Nonalcoholic Steatohepatitis
    • 2.4.3 Regulate Blood Lipid
    • 2.4.4 Others
  • 2.5 PPARα Agonist Sales by Application
    • 2.5.1 Global PPARα Agonist Sale Market Share by Application (2017-2022)
    • 2.5.2 Global PPARα Agonist Revenue and Market Share by Application (2017-2022)
    • 2.5.3 Global PPARα Agonist Sale Price by Application (2017-2022)

3 Global PPARα Agonist by Company

  • 3.1 Global PPARα Agonist Breakdown Data by Company
    • 3.1.1 Global PPARα Agonist Annual Sales by Company (2020-2022)
    • 3.1.2 Global PPARα Agonist Sales Market Share by Company (2020-2022)
  • 3.2 Global PPARα Agonist Annual Revenue by Company (2020-2022)
    • 3.2.1 Global PPARα Agonist Revenue by Company (2020-2022)
    • 3.2.2 Global PPARα Agonist Revenue Market Share by Company (2020-2022)
  • 3.3 Global PPARα Agonist Sale Price by Company
  • 3.4 Key Manufacturers PPARα Agonist Producing Area Distribution, Sales Area, Product Type
    • 3.4.1 Key Manufacturers PPARα Agonist Product Location Distribution
    • 3.4.2 Players PPARα Agonist Products Offered
  • 3.5 Market Concentration Rate Analysis
    • 3.5.1 Competition Landscape Analysis
    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
  • 3.6 New Products and Potential Entrants
  • 3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for PPARα Agonist by Geographic Region

  • 4.1 World Historic PPARα Agonist Market Size by Geographic Region (2017-2022)
    • 4.1.1 Global PPARα Agonist Annual Sales by Geographic Region (2017-2022)
    • 4.1.2 Global PPARα Agonist Annual Revenue by Geographic Region
  • 4.2 World Historic PPARα Agonist Market Size by Country/Region (2017-2022)
    • 4.2.1 Global PPARα Agonist Annual Sales by Country/Region (2017-2022)
    • 4.2.2 Global PPARα Agonist Annual Revenue by Country/Region
  • 4.3 Americas PPARα Agonist Sales Growth
  • 4.4 APAC PPARα Agonist Sales Growth
  • 4.5 Europe PPARα Agonist Sales Growth
  • 4.6 Middle East & Africa PPARα Agonist Sales Growth

5 Americas

  • 5.1 Americas PPARα Agonist Sales by Country
    • 5.1.1 Americas PPARα Agonist Sales by Country (2017-2022)
    • 5.1.2 Americas PPARα Agonist Revenue by Country (2017-2022)
  • 5.2 Americas PPARα Agonist Sales by Type
  • 5.3 Americas PPARα Agonist Sales by Application
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC PPARα Agonist Sales by Region
    • 6.1.1 APAC PPARα Agonist Sales by Region (2017-2022)
    • 6.1.2 APAC PPARα Agonist Revenue by Region (2017-2022)
  • 6.2 APAC PPARα Agonist Sales by Type
  • 6.3 APAC PPARα Agonist Sales by Application
  • 6.4 China
  • 6.5 Japan
  • 6.6 South Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia
  • 6.10 China Taiwan

7 Europe

  • 7.1 Europe PPARα Agonist by Country
    • 7.1.1 Europe PPARα Agonist Sales by Country (2017-2022)
    • 7.1.2 Europe PPARα Agonist Revenue by Country (2017-2022)
  • 7.2 Europe PPARα Agonist Sales by Type
  • 7.3 Europe PPARα Agonist Sales by Application
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa PPARα Agonist by Country
    • 8.1.1 Middle East & Africa PPARα Agonist Sales by Country (2017-2022)
    • 8.1.2 Middle East & Africa PPARα Agonist Revenue by Country (2017-2022)
  • 8.2 Middle East & Africa PPARα Agonist Sales by Type
  • 8.3 Middle East & Africa PPARα Agonist Sales by Application
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers
  • 10.2 Manufacturing Cost Structure Analysis of PPARα Agonist
  • 10.3 Manufacturing Process Analysis of PPARα Agonist
  • 10.4 Industry Chain Structure of PPARα Agonist

11 Marketing, Distributors and Customer

  • 11.1 Sales Channel
    • 11.1.1 Direct Channels
    • 11.1.2 Indirect Channels
  • 11.2 PPARα Agonist Distributors
  • 11.3 PPARα Agonist Customer

12 World Forecast Review for PPARα Agonist by Geographic Region

  • 12.1 Global PPARα Agonist Market Size Forecast by Region
    • 12.1.1 Global PPARα Agonist Forecast by Region (2023-2028)
    • 12.1.2 Global PPARα Agonist Annual Revenue Forecast by Region (2023-2028)
  • 12.2 Americas Forecast by Country
  • 12.3 APAC Forecast by Region
  • 12.4 Europe Forecast by Country
  • 12.5 Middle East & Africa Forecast by Country
  • 12.6 Global PPARα Agonist Forecast by Type
  • 12.7 Global PPARα Agonist Forecast by Application

13 Key Players Analysis

  • 13.1 Ross Organic
    • 13.1.1 Ross Organic Company Information
    • 13.1.2 Ross Organic PPARα Agonist Product Offered
    • 13.1.3 Ross Organic PPARα Agonist Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.1.4 Ross Organic Main Business Overview
    • 13.1.5 Ross Organic Latest Developments
  • 13.2 BASF
    • 13.2.1 BASF Company Information
    • 13.2.2 BASF PPARα Agonist Product Offered
    • 13.2.3 BASF PPARα Agonist Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.2.4 BASF Main Business Overview
    • 13.2.5 BASF Latest Developments
  • 13.3 Abmole
    • 13.3.1 Abmole Company Information
    • 13.3.2 Abmole PPARα Agonist Product Offered
    • 13.3.3 Abmole PPARα Agonist Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.3.4 Abmole Main Business Overview
    • 13.3.5 Abmole Latest Developments
  • 13.4 DXTPHARM
    • 13.4.1 DXTPHARM Company Information
    • 13.4.2 DXTPHARM PPARα Agonist Product Offered
    • 13.4.3 DXTPHARM PPARα Agonist Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.4.4 DXTPHARM Main Business Overview
    • 13.4.5 DXTPHARM Latest Developments
  • 13.5 Ruiweier
    • 13.5.1 Ruiweier Company Information
    • 13.5.2 Ruiweier PPARα Agonist Product Offered
    • 13.5.3 Ruiweier PPARα Agonist Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.5.4 Ruiweier Main Business Overview
    • 13.5.5 Ruiweier Latest Developments
  • 13.6 BACHEM
    • 13.6.1 BACHEM Company Information
    • 13.6.2 BACHEM PPARα Agonist Product Offered
    • 13.6.3 BACHEM PPARα Agonist Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.6.4 BACHEM Main Business Overview
    • 13.6.5 BACHEM Latest Developments
  • 13.7 Zydus Cadila
    • 13.7.1 Zydus Cadila Company Information
    • 13.7.2 Zydus Cadila PPARα Agonist Product Offered
    • 13.7.3 Zydus Cadila PPARα Agonist Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.7.4 Zydus Cadila Main Business Overview
    • 13.7.5 Zydus Cadila Latest Developments
  • 13.8 InvivoChem
    • 13.8.1 InvivoChem Company Information
    • 13.8.2 InvivoChem PPARα Agonist Product Offered
    • 13.8.3 InvivoChem PPARα Agonist Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.8.4 InvivoChem Main Business Overview
    • 13.8.5 InvivoChem Latest Developments
  • 13.9 APEXBIO
    • 13.9.1 APEXBIO Company Information
    • 13.9.2 APEXBIO PPARα Agonist Product Offered
    • 13.9.3 APEXBIO PPARα Agonist Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.9.4 APEXBIO Main Business Overview
    • 13.9.5 APEXBIO Latest Developments
  • 13.10 Abcam
    • 13.10.1 Abcam Company Information
    • 13.10.2 Abcam PPARα Agonist Product Offered
    • 13.10.3 Abcam PPARα Agonist Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.10.4 Abcam Main Business Overview
    • 13.10.5 Abcam Latest Developments
  • 13.11 Weikeqi-biotech
    • 13.11.1 Weikeqi-biotech Company Information
    • 13.11.2 Weikeqi-biotech PPARα Agonist Product Offered
    • 13.11.3 Weikeqi-biotech PPARα Agonist Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.11.4 Weikeqi-biotech Main Business Overview
    • 13.11.5 Weikeqi-biotech Latest Developments
  • 13.12 Solarbio
    • 13.12.1 Solarbio Company Information
    • 13.12.2 Solarbio PPARα Agonist Product Offered
    • 13.12.3 Solarbio PPARα Agonist Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.12.4 Solarbio Main Business Overview
    • 13.12.5 Solarbio Latest Developments
  • 13.13 Nznutritionals
    • 13.13.1 Nznutritionals Company Information
    • 13.13.2 Nznutritionals PPARα Agonist Product Offered
    • 13.13.3 Nznutritionals PPARα Agonist Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.13.4 Nznutritionals Main Business Overview
    • 13.13.5 Nznutritionals Latest Developments
  • 13.14 WEL-BLOOM Bio-Tech Corporation
    • 13.14.1 WEL-BLOOM Bio-Tech Corporation Company Information
    • 13.14.2 WEL-BLOOM Bio-Tech Corporation PPARα Agonist Product Offered
    • 13.14.3 WEL-BLOOM Bio-Tech Corporation PPARα Agonist Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.14.4 WEL-BLOOM Bio-Tech Corporation Main Business Overview
    • 13.14.5 WEL-BLOOM Bio-Tech Corporation Latest Developments
  • 13.15 Young Nutraceuticals
    • 13.15.1 Young Nutraceuticals Company Information
    • 13.15.2 Young Nutraceuticals PPARα Agonist Product Offered
    • 13.15.3 Young Nutraceuticals PPARα Agonist Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.15.4 Young Nutraceuticals Main Business Overview
    • 13.15.5 Young Nutraceuticals Latest Developments
  • 13.16 Biorbyt
    • 13.16.1 Biorbyt Company Information
    • 13.16.2 Biorbyt PPARα Agonist Product Offered
    • 13.16.3 Biorbyt PPARα Agonist Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.16.4 Biorbyt Main Business Overview
    • 13.16.5 Biorbyt Latest Developments
  • 13.17 BIOSYNTH
    • 13.17.1 BIOSYNTH Company Information
    • 13.17.2 BIOSYNTH PPARα Agonist Product Offered
    • 13.17.3 BIOSYNTH PPARα Agonist Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.17.4 BIOSYNTH Main Business Overview
    • 13.17.5 BIOSYNTH Latest Developments
  • 13.18 TargetMol
    • 13.18.1 TargetMol Company Information
    • 13.18.2 TargetMol PPARα Agonist Product Offered
    • 13.18.3 TargetMol PPARα Agonist Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.18.4 TargetMol Main Business Overview
    • 13.18.5 TargetMol Latest Developments
  • 13.19 Bjbalb
    • 13.19.1 Bjbalb Company Information
    • 13.19.2 Bjbalb PPARα Agonist Product Offered
    • 13.19.3 Bjbalb PPARα Agonist Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.19.4 Bjbalb Main Business Overview
    • 13.19.5 Bjbalb Latest Developments
  • 13.20 Amgicam
    • 13.20.1 Amgicam Company Information
    • 13.20.2 Amgicam PPARα Agonist Product Offered
    • 13.20.3 Amgicam PPARα Agonist Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.20.4 Amgicam Main Business Overview
    • 13.20.5 Amgicam Latest Developments
  • 13.21 Lupin
    • 13.21.1 Lupin Company Information
    • 13.21.2 Lupin PPARα Agonist Product Offered
    • 13.21.3 Lupin PPARα Agonist Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.21.4 Lupin Main Business Overview
    • 13.21.5 Lupin Latest Developments

14 Research Findings and Conclusion

Summary:
Get latest Market Research Reports on PPARα Agonist. Industry analysis & Market Report on PPARα Agonist is a syndicated market report, published as Global PPARα Agonist Market Growth 2022-2028. It is complete Research Study and Industry Analysis of PPARα Agonist market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

Last updated on

REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$3,660.00
$7,320.00
3,030.48
6,060.96
3,517.26
7,034.52
509,618.40
1,019,236.80
299,022.00
598,044.00
Credit card Logo

Related Reports


Reason to Buy

Request for Sample of this report